JP2022507830A5 - - Google Patents

Info

Publication number
JP2022507830A5
JP2022507830A5 JP2021527959A JP2021527959A JP2022507830A5 JP 2022507830 A5 JP2022507830 A5 JP 2022507830A5 JP 2021527959 A JP2021527959 A JP 2021527959A JP 2021527959 A JP2021527959 A JP 2021527959A JP 2022507830 A5 JP2022507830 A5 JP 2022507830A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
modified
cells
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021527959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507830A (ja
Filing date
Publication date
Priority claimed from US16/445,965 external-priority patent/US10918667B2/en
Application filed filed Critical
Priority claimed from PCT/US2019/062417 external-priority patent/WO2020106843A1/en
Publication of JP2022507830A publication Critical patent/JP2022507830A/ja
Publication of JP2022507830A5 publication Critical patent/JP2022507830A5/ja
Pending legal-status Critical Current

Links

JP2021527959A 2018-11-20 2019-11-20 治療薬を発現する改変細胞とその使用 Pending JP2022507830A (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201862769987P 2018-11-20 2018-11-20
US62/769,987 2018-11-20
US201862774595P 2018-12-03 2018-12-03
US62/774,595 2018-12-03
US201962795810P 2019-01-23 2019-01-23
US62/795,810 2019-01-23
US201962828770P 2019-04-03 2019-04-03
US62/828,770 2019-04-03
US201962846563P 2019-05-10 2019-05-10
US62/846,563 2019-05-10
US201962848961P 2019-05-16 2019-05-16
US62/848,961 2019-05-16
US16/445,965 2019-06-19
US16/445,965 US10918667B2 (en) 2018-11-20 2019-06-19 Modified cell expressing therapeutic agent and uses thereof
US201962889926P 2019-08-21 2019-08-21
US62/889,926 2019-08-21
US201962902766P 2019-09-19 2019-09-19
US62/902,766 2019-09-19
PCT/US2019/062417 WO2020106843A1 (en) 2018-11-20 2019-11-20 Modified cell expressing therapeutic agent and uses thereof

Publications (2)

Publication Number Publication Date
JP2022507830A JP2022507830A (ja) 2022-01-18
JP2022507830A5 true JP2022507830A5 (cg-RX-API-DMAC7.html) 2022-11-29

Family

ID=70774027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021527959A Pending JP2022507830A (ja) 2018-11-20 2019-11-20 治療薬を発現する改変細胞とその使用

Country Status (7)

Country Link
US (2) US20220000921A1 (cg-RX-API-DMAC7.html)
EP (1) EP3883585A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022507830A (cg-RX-API-DMAC7.html)
AU (1) AU2019384145A1 (cg-RX-API-DMAC7.html)
CA (1) CA3120153A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105173VA (cg-RX-API-DMAC7.html)
WO (1) WO2020106843A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
BR112020025287A2 (pt) * 2018-06-25 2021-03-09 University Of Washington Projeto de novo de miméticos de interleucina potentes e seletivos
US12410226B2 (en) 2018-07-30 2025-09-09 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
CN112638947B (zh) * 2018-08-30 2022-09-30 上海斯丹赛生物技术有限公司 用于治疗实体瘤的嵌合抗原受体细胞
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
JP2022511390A (ja) 2018-11-20 2022-01-31 ユニバーシティ オブ ワシントン 分割インターロイキン模倣体およびその使用
JP2022531814A (ja) * 2019-03-12 2022-07-12 イノベイティブ セルラー セラピューティクス ホールディングス,エルティディ 改変細胞の増幅およびその応用
WO2021016194A1 (en) 2019-07-19 2021-01-28 Racaniello Vincent R Second generation seneca valley virus oncolytic therapy: compositions and methods thereof
US12702708B2 (en) 2019-08-21 2026-08-11 Innovative Cellular Therapeutics Holdings, Ltd. Presenting cell and use thereof in cell therapy
US20210060069A1 (en) * 2019-08-23 2021-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Coupled redirected cells and uses thereof
BR112022009110A2 (pt) * 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
WO2021179967A1 (zh) * 2020-03-09 2021-09-16 四川大学华西医院 IFN-γ在制备抗肿瘤辅助药物中的应用
EP3892720A1 (en) 2020-04-06 2021-10-13 Innovative Cellular Therapeutics Holdings, Ltd. Presenting cell and use thereof in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
JP7633377B2 (ja) * 2020-07-27 2025-02-19 中国科学院分子細胞科学卓越創新中心 キメラ抗原受容体及びその用途
US20230303975A1 (en) * 2020-08-21 2023-09-28 Julius-Maximilians-Universität Würzburg Modified lymphocytes
WO2022079489A1 (en) * 2020-10-12 2022-04-21 Takeda Pharmaceutical Company Limited Determination of cellular kinetics and biodistribution for car-t cells
WO2022159508A1 (en) * 2021-01-19 2022-07-28 Seneca Therapeutics, Inc. Armed seneca valley virus oncolytic therapy compositions and methods thereof
US11633427B2 (en) * 2021-02-05 2023-04-25 Innovative Cellular Therapeutics Holdings, Ltd. Vaccine and uses thereof in cell therapy
CN113046320B (zh) * 2021-02-19 2023-04-14 中国医学科学院基础医学研究所 胞外段为Vδ1(GTM)Vγ4的CAR分子及表达该分子的CAR-T细胞及其用途
WO2022216144A1 (en) * 2021-04-08 2022-10-13 GC Cell Corporation Fusion proteins comprising chimeric antigen receptors and il-15
CN114934071B (zh) * 2021-04-30 2023-10-17 四川大学华西医院 一种表达免疫调节因子的car载体及其应用
EP4215245A1 (en) 2022-01-19 2023-07-26 Innovative Cellular Therapeutics Holdings, Ltd. Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment
EP4739334A1 (en) 2023-07-05 2026-05-13 Nanotein Technologies, Inc. Cell signaling complexes and uses thereof
US12473529B2 (en) 2023-07-18 2025-11-18 Nanotein Technologies, Inc. Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
WO2025117789A1 (en) * 2023-12-01 2025-06-05 Parker Institute For Cancer Immunotherapy Engineered immune signaling constructs
WO2025184172A1 (en) * 2024-02-27 2025-09-04 Overt Bio, Inc. Cancer reactive t cell receptors
WO2025184170A1 (en) 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2292242T5 (es) * 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
JP2003513681A (ja) * 1999-11-12 2003-04-15 マキシゲン・ホールディングス・リミテッド インターフェロンガンマ・コンジュゲート
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2508831C (en) * 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
AU2010205782A1 (en) * 2009-01-16 2011-09-08 Agirx Limited Vaccine compositions
WO2010126766A1 (en) * 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
JP5975983B2 (ja) * 2010-04-16 2016-08-23 ベリカム ファーマシューティカルズ, インコーポレイテッド 固形腫瘍を処置するための方法
WO2012066495A2 (en) * 2010-11-17 2012-05-24 Ben Gurion University Of The Negev Research And Development Authority T-cell therapy to neurodegenerative diseases
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP2014509841A (ja) * 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
AU2012267710A1 (en) * 2011-06-08 2014-01-23 The Regents Of The University Of California Anti-CD22 antigen binding molecules to treat lung cancer and prostate cancer
JP6267644B2 (ja) * 2011-10-20 2018-01-24 アメリカ合衆国 抗cd22キメラ抗原受容体
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
WO2016113203A1 (en) * 2015-01-12 2016-07-21 Pieris Ag Engineered t cells and uses therefor
US10493139B2 (en) * 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
SG10201913151TA (en) * 2015-09-09 2020-03-30 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Genetic engineering of macrophages for immunotherapy
WO2017075537A1 (en) * 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
SG11201807489PA (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN113082201B (zh) * 2016-04-01 2024-07-05 上海斯丹赛生物技术有限公司 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
KR102614675B1 (ko) * 2016-04-15 2023-12-19 메모리얼 슬로안 케터링 캔서 센터 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
CN118165113B (zh) * 2016-04-26 2025-10-28 恺兴生命科技(上海)有限公司 一种改善免疫应答细胞功能的方法
WO2018064921A1 (en) * 2016-10-06 2018-04-12 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
EP3571294A1 (en) * 2017-01-18 2019-11-27 F1 Oncology, Inc. Methods of transducing and expanding immune cells and uses thereof
US10561686B2 (en) * 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof

Similar Documents

Publication Publication Date Title
FI3844267T3 (fi) Menetelmät kimeeristä antigeenireseptoria ilmentävien solujen valmistamiseksi
JP2019525956A5 (cg-RX-API-DMAC7.html)
JP2017513818A5 (cg-RX-API-DMAC7.html)
JP2024518011A5 (cg-RX-API-DMAC7.html)
JP2021532742A5 (cg-RX-API-DMAC7.html)
IL295604A (en) Methods of making chimeric antigen receptor-expressing cells
JP2019516350A5 (cg-RX-API-DMAC7.html)
JP2021534783A5 (cg-RX-API-DMAC7.html)
JP2024521566A5 (cg-RX-API-DMAC7.html)
JP2023516008A5 (cg-RX-API-DMAC7.html)
JP2022523781A5 (cg-RX-API-DMAC7.html)
JP2021518142A5 (cg-RX-API-DMAC7.html)
JP2019518424A5 (cg-RX-API-DMAC7.html)
JP2018527014A5 (cg-RX-API-DMAC7.html)
JP2024510900A5 (cg-RX-API-DMAC7.html)
JP2019513347A5 (cg-RX-API-DMAC7.html)
RU2019133286A (ru) Биомаркеры и средства терапии на основе т-клеток с car с повышенной эффективностью
HRP20221348T1 (hr) Kimerni receptori i postupci njihove uporabe
JP2018527008A5 (cg-RX-API-DMAC7.html)
FI3380620T3 (fi) Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja
JP2019516352A5 (cg-RX-API-DMAC7.html)
JP2019500394A5 (cg-RX-API-DMAC7.html)
JP2022548796A5 (cg-RX-API-DMAC7.html)
JP2023549098A5 (cg-RX-API-DMAC7.html)
JP2023525720A5 (cg-RX-API-DMAC7.html)